European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Igyxos SA, Nouzilly, France

Watch
Igyxos SA

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Create Dossier
Igyxos SA

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Risk report
Igyxos SA
Risk Level Evaluation Source
Sanctioned (?)
Anti-trust proceedings (?)

Name

Igyxos SA

Identification

Sirul
Siren 830854808
Siret
Siret 83085480800011
EUID
FR3701.830854808

Address

Centre Inra Val de Loire, 37380 Nouzilly, France

Corporate purpose

72.11
Research and experimental development on biotechnology

Preclinical and clinical development, production and marketing of products for human therapeutic purposes

History

Persons

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
1Chair of the board
2President
2Director-General
1Deputy Director-General
1Director
1Director
1Member of the board
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

15 Mar 2026
Capital: €348,276
14 Jan 2025
Director-General: Florent Marc Ferré · No longer Director-General: François Desmarest · Capital: €207,246
14 Jan 2025
Capital: €292,746
14 Jan 2025
Capital: €321,804
28 Jul 2024
Director-General: François Desmarest · No longer Director-General (1) · Capital: €207,246
18 Feb 2024
President: Sylvie E. Bove · Deputy Director-General: Marie-Ch. Redor · Capital: €207,246
1 Feb 2024
Director: Sylvie Bove · Capital: €135,024
28 Nov 2023
Patent: Humanized variants Antibodies or fragments of which are used to increase gonadotropin bioactivity
1 Sept 2023
Director-General (1) · Capital: €135,024
23 Aug 2023
No longer Director-General: Pierre Longeray · Director-General (1)
3 Aug 2022
Dismissed: Sofimac Innovation · Capital: €135,024
25 Jul 2022
Member of the board: UI Investissement SAS · No longer Member of the board: Sofimac Innovation SAS
28 Apr 2022
Reg­is­tra­tion: 28/04/2022 · Address · Legal form: SA à conseil d'administration (s.a.i.) · Name: IGYXOS · Segment clas­si­fi­ca­tion
20 Oct 2021
Capital: €135,024
27 Jun 2021
Director (1) · Director: Eden Biotech Sàrl · Capital: €82,434
21 Jun 2021
President: Marie-Ch. Redor · Director: Eden Biotech Sàrl
17 Jun 2021
Director: Eden Biotech Sàrl
30 Dec 2020
Patent: Ligands That Potentiate the Bioactivity of Gonadotropins
27 Nov 2020
Capital: €61,404
27 Nov 2020
Capital: €82,434
8 Jul 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
3 May 2019
Pres.: Marie-Ch. Maurel · DG: Pierre Longeray · No longer Chair SB: François R. Gounelle · No longer VP: Jean Decor · No longer SB (4) · No longer SB: Apicap, Centre Capital Developpement …
23 Apr 2019
President: Marie-Ch. Redor · DG: Pierre Longeray · No longer Pres.: François R. Gounelle · No longer VP: Jean Decor · No longer SB (4) · No longer SB: Apicap SAS, Centre Capital Developpement SA
26 Feb 2019
Legal form: SA à conseil d'administration (s.a.i.)
19 Jul 2017 as Igyxos SA à directoire et conseil de surveillance
Capital: €39,474 · Corporate Purpose
13 Jul 2017
President: François R. Gounelle · Director-General: Marie-Ch. Redor · Vice president: Jean Decor · SB (4) · SB: Apicap SAS, Centre Capital Developpement SA · Auditor: TGS France Audit SAS
8 Jun 2017
Address · Legal form: SA à directoire (s.a.i.) · Name: IGYXOS · Segment clas­si­fi­ca­tion
There are no publications matching your search.

Mentions

27 Jul 2026 in Rne
Reg­is­tra­tion: 08/06/2017 · DG: Florent Marc Ferré · Chair: Sylvie E. Bove · Dep.DG: Marie-Ch. Redor · Director: Eden Biotech Sàrl, GO Capital SAS · Auditor: TGS France Audit SAS · Capital: €348,276
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.